Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicenter retrospective study (Moga-stop study)
Sofia Tzoumpa
(1)
,
Saskia Ingen-Housz-Oro
(2, 1)
,
Adèle de Masson
(3, 4)
,
Anne Pham-Ledard
(5, 6)
,
Tarik El Aarbaoui
(2)
,
Olivier Dereure
(7)
,
Gaëlle Quereux
(8, 9, 10)
,
Sarah Faiz
(11)
,
Marine de Vicq de Cumptich
(12, 13)
,
Caroline Ram-Wolff
(3, 4)
,
Raphaël Janela-Lapert
(14)
,
Emmanuella Guenova
(15, 16)
,
Coralie Lheure
(17)
,
Yannick Le Corre
(18)
,
Henri Adamski
(19)
,
Maël Blanchard
(15, 20)
,
Nathalie Bonnet
(21)
,
Florent Amatore
(21)
,
Florent Grange
(22)
,
Laura Troin
(23)
,
Martine Bagot
(3, 4)
,
Marie Beylot-Barry
(5, 6)
1
Hôpital Henri Mondor
2 EpiDermE - Epidemiology in Dermatology and Evaluation in Therapeutics
3 AP-HP - Hopital Saint-Louis [AP-HP]
4 UPCité - Université Paris Cité
5 Inserm U1312 - BRIC - BoRdeaux Institute in onCology
6 CHU Bordeaux - Centre Hospitalier Universitaire de Bordeaux
7 CHU Montpellier = Montpellier University Hospital
8 INCIT - Immunology and New Concepts in ImmunoTherapy
9 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
10 CIC Nantes - Centre d’Investigation Clinique de Nantes
11 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
12 CHU - Centre Hospitalier Universitaire Brugmann [Bruxelles]
13 Institut Jules Bordet [Bruxelles]
14 CHU Rouen
15 UNIL - Université de Lausanne = University of Lausanne
16 CHUV - Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne]
17 Hôpital Cochin [AP-HP]
18 CHU Angers - Centre Hospitalier Universitaire d'Angers
19 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
20 Geneva University Hospitals and Geneva University
21 Hôpital Nord [CHU - APHM]
22 Centre hospitalier de Valence
23 CHU Nice - Centre Hospitalier Universitaire de Nice
2 EpiDermE - Epidemiology in Dermatology and Evaluation in Therapeutics
3 AP-HP - Hopital Saint-Louis [AP-HP]
4 UPCité - Université Paris Cité
5 Inserm U1312 - BRIC - BoRdeaux Institute in onCology
6 CHU Bordeaux - Centre Hospitalier Universitaire de Bordeaux
7 CHU Montpellier = Montpellier University Hospital
8 INCIT - Immunology and New Concepts in ImmunoTherapy
9 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
10 CIC Nantes - Centre d’Investigation Clinique de Nantes
11 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
12 CHU - Centre Hospitalier Universitaire Brugmann [Bruxelles]
13 Institut Jules Bordet [Bruxelles]
14 CHU Rouen
15 UNIL - Université de Lausanne = University of Lausanne
16 CHUV - Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne]
17 Hôpital Cochin [AP-HP]
18 CHU Angers - Centre Hospitalier Universitaire d'Angers
19 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
20 Geneva University Hospitals and Geneva University
21 Hôpital Nord [CHU - APHM]
22 Centre hospitalier de Valence
23 CHU Nice - Centre Hospitalier Universitaire de Nice
Saskia Ingen-Housz-Oro
- Fonction : Auteur
- PersonId : 814296
- ORCID : 0000-0002-5383-7096
Tarik El Aarbaoui
- Fonction : Auteur
- PersonId : 1253745
- IdHAL : tarik-el-aarbaoui
- ORCID : 0000-0003-1323-6226
Maël Blanchard
- Fonction : Auteur
- PersonId : 1378260
- ORCID : 0000-0001-9955-7172
Marie Beylot-Barry
- Fonction : Auteur
- PersonId : 762790
- ORCID : 0000-0001-6150-1229
- IdRef : 05956427X
Résumé
The results of this study suggest that a progressive discontinuation of mogamulizumab should be considered once response is obtained in Sezary syndrome patients, even after a treatment of short-duration. This may possibly minimize the risk of adverse effects, costs, and resistance to mogamulizumab. Additionally, our study emphasizes that mogamulizumab rechallenge should be encouraged as first-choice for relapsing patients.
No abstract available